ReviewAnnals of medicine and surgery (2012)2025
Neurotoxic effects of the chemotherapeutic drug "methotrexate": a literature review.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and Mechanistic Divergence of Seizures in Pediatric Acute Lymphoblastic Leukemia: CNS Infiltration Versus Chemotherapy-Induced Neurotoxicity.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methotrexate (MTX) is currently considered the go-to drug in chemotherapy, although it possesses neurological dangers. In this review paper, research and records of MTX-induced neurotoxicity in different types of adult and pediatric cancers will be discussed. The general description and function of MTX are still not completely known. How biological ratios in the body fluctuate with low and high methotrexate doses are still unknown as well. Therefore, this is a hot topic for experts, especially those active in neuro-oncology research. Scientists and physicians are now using different protocols to understand, control, manage, and prevent MTX-neurotoxic events. Aim: By evaluating various studies, case reports, and clinical trials, this comprehensive review seeks to clarify the mechanisms underlying MTX-induced neurotoxicity, highlight potential strategies for prevention and management, and guide future research in mitigating the adverse neurological effects of MTX treatment. Methods: Several databases were employed to gather this information, mainly PubMed. Results: The precise mechanisms of MTX-induced neurotoxicity remain unclear. Multiple hypotheses suggest involvement of genes related to neurogenesis, but no definitive cause has been identified. Regular patient monitoring, long-term follow-up, variable therapies, and early MRI detection are recommended. Conclusion: Despite advancements, no longitudinal studies have conclusively determined effective strategies to prevent MTX-induced neurotoxicity. Demographic factors and cancer types do not consistently predict neurotoxicity. Future research should focus on genetic counseling prior to chemotherapy, targeted monitoring protocols, and long-term patient follow-up to better understand and mitigate the neurotoxic impacts of MTX. Pharmacokinetics and advanced neuroimaging techniques are also essential for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.